On March 25, 2026, 4D Molecular Therapeutics, Inc. announced the appointment of Kristian Humer as the company's Principal Accounting Officer, effective immediately. Humer succeeds Ashoo Gupta, who will continue in his role as Vice President, Finance and Controller. Humer, age 51, has been with the company since November 2025, serving as the Chief Financial Officer and Principal Financial Officer. His previous experience includes serving as Chief Financial Officer at Foghorn Therapeutics, Inc. and various roles at Citigroup Global Markets Inc., where he was Managing Director in the Healthcare Investment Banking Group. Humer holds an MBA from Duke University's Fuqua School of Business and a BA in Accounting & Economics from the University of Reading. This leadership change is expected to enhance the financial oversight of the company as it continues to navigate the complexities of the biotechnology sector.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.